Interpace Biosciences, Inc. (MUN:PF4)

Market Cap	27.26M +671.2%
Revenue (ttm)	31.64M -20.5%
Net Income	21.40M +435.6%
EPS	4.00 +24.1%
Shares Out	n/a
PE Ratio	1.60
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	6.40
Previous Close	6.40
Day's Range	6.40 - 6.40
52-Week Range	5.35 - 8.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 11, 2026

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and cha...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1986
• Employees: 102
• Stock Exchange: Munich Stock Exchange
• Ticker Symbol: PF4

Financial Performance

In 2025, Interpace Biosciences's revenue was $38.73 million, a decrease of -17.47% compared to the previous year's $46.93 million. Earnings were $24.58 million, an increase of 293.96%.

Financial numbers in USD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 28, 2026

Data Sources Report a data error